About Us
Corporate Overview
Executive Leadership
Management team
Scientific Advisory Board
Board of Directors
Clinical Advisory Board
Our Science
Pipeline
Overview
AG-73305
AG-80308
AG-86893
Disease
Overview
DME
nAMD
Other Diseases
Pterygium
Dry Eye
Clinical Trial
Investor Relations
Investors
Press Release & Publications
Allgenesis In The News
Contact Us
Press Release & Publications
Filter by
Categories
Tags
Authors
Show all
All
News
All
2015
2018
2019
2020
2021
2022
2023
All
admin
allgenesis
sky
2020-02-05
Allgenesis Receives Notice of Grant of Japanese Patent for anti-VEGF/Disintegrin Fusion Protein
Taipei, Taiwan/ February 4th, 2020 Allge
[…]
2020-01-21
Allgenesis: Final Database Lock Reaffirms Excellent Safety, Tolerability, and Signs of Efficacy from POC Phase 2a Study of AG-86893 in Patients with Pterygium
Taipei, Taiwan/ January 21st, 2020 Allge
[…]
2019-11-14
Allgenesis Program Selected for RESI Taipei Innovation Challenge
Taipei, Taiwan/ November 14th, 2019 Allg
[…]
2019-10-18
Allgenesis sees Excellent Safety, Tolerability, and Signs of Efficacy from its Ongoing POC Phase 2a Study of AG-86893 in Patients with Pterygium
Taipei, Taiwan/ October 18th, 2019 Allge
[…]
2019-09-25
Allgenesis Provides Timing Update of SURPH Phase 2a Clinical Trial for AG-86893 for the Treatment of Pterygium
September 25th, 2019 Allgenesis Biothera
[…]
2019-06-11
CEO Dr. Cherukury Interviewed by Macular Degeneration Foundation at the 2019 ARVO Conference
June 11th, 2019 Allgenesis In the News:
[…]
Load more